GSK Files Lawsuit Against Pfizer for RSV Vaccine Patent Infringement

GlaxoSmithKline (GSK) has filed a lawsuit against Pfizer in a U.S. court, accusing the company of patent infringement over GSK's respiratory syncytial virus (RSV) vaccine. GSK claims that Pfizer's RSV vaccine, Abrysvo, infringes on four of its patents related to the antigen used in its own shot. Both vaccines were recently approved by the FDA for use in adults 60 and above, and GSK alleges that Pfizer knowingly uses its inventions without permission. Pfizer has stated that it is confident in its intellectual property position and will defend its right to bring its RSV shot to patients. RSV is a common respiratory infection that can cause severe symptoms in older adults and children, and GSK's lawsuit highlights the importance of protecting intellectual property in the healthcare industry.